Abstract
We identified 19 persons with B-cell chronic lymphocytic leukemia (CLL) who received genetically identical twin blood cell or bone marrow transplants after high-dose conditioning. Ten are alive (eight disease-free) with a median follow-up of 89 months (range, 31–171 months); 5-year relapse rate was 50% (95% confidence interval (CI), 26–73%). Estimated 5-year survival and disease-free survival were 61% (95% CI, 37–82%) and 45% (95% CI, 23–68%). In two of four patients tested at 12 and 21 months by polymerase chain reaction no evidence of residual CLL was detected post-transplant. In one recipient who relapsed at 6 years, molecular studies showed a different CLL clone from that detected pretransplant. This clone was subsequently identified in the donor suggesting transfer of occult leukemia at the time of transplant. Genetically identical twin transplants can result in long-term disease-free survival and molecular remissions, these data suggest the potential for CLL control in the absence of allogeneic graft-versus-leukemia effect. The case of leukemia transfer indicates the need for careful evaluation of donors prior to graft collection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646–652.
Gahrton G, Svensson H, Bjorkstrand B, Apperley J, Carlson K, Cavo M et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European group for blood and marrow transplantation. Bone Marrow Transplant 1999; 24: 741–745.
Barrett AJ, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323–3327.
Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoietic stem-cell transplantation for non-hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation—the Lymphoma working committee of the international bone marrow transplant registry and the European group for blood and marrow transplantation. J Clin Oncol 2003; 21: 3744–3753.
Kroger N, Brand R, van Biezen A, Bron D, Blaise D, Hellstrom-Lindberg E et al. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. Bone Marrow Transplant 2005; 35: 37–43.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 1996; 17: 775–779.
Kanfer EJ, Buckner CD, Fefer A, Storb R, Appelbaum FR, Hill RS et al. Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation. Bone Marrow Transplant 1987; 1: 339–346.
Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602.
Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433–3438.
Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J Clin Oncol 2005; 23: 5788–5794.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the cooperative German transplant study group. J Clin Oncol 2003; 21: 2747–2753.
Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–3829.
Pavletic ZS, Bierman PJ, Vose JM, Bishop MR, Wu CD, Pierson JL et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 1998; 9: 1023–1026.
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.
Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15: 445–451.
Wu GQ, Sharp JG, Wu G, Vose J, Greiner TC, Chan WC . The detection of minimal lymphoma by molecular and combined culture-molecular methods. Br J Haematol 1997; 99: 873–881.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F . How I treat refractory CLL? Blood 2006; 107: 1276–1283.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al. Environmental and heritable factors in the causation of cancer — analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.
Aoun P, Zhou G, Chan WC, Page C, Neth K, Pickering D et al. Familial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. Am J Clin Pathol 2007; 127: 31–38.
Brok-Simoni F, Rechavi G, Katzir N, Ben-Bassat I . Chronic lymphocytic leukaemia in twin sisters: monozygous but not identical. Lancet 1987; 1: 329–330.
Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002; 100: 2289–2290.
Marti GE, Carter P, Abbasi F, Washington GC, Jain N, Zenger VE et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom 2003; 52: 1–12.
Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA et al. Monoclonal B lymphocytes with the characteristics of ‘indolent’ chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100: 635–639.
Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103: 2337–2342.
Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Ponisch W et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant 2004; 34: 657–665.
Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 511–517.
Kiss TL, Chang H, Daly A, Messner HA, Jamal N, Spaner D et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals. Bone Marrow Transplant 2004; 33: 855–858.
Acknowledgements
We want to specifically acknowledge European Group for Blood and Marrow Transplantation (EBMT) for the enthusiastic commitment and contributions to this study. We thank Dr Mark DeWolfe of Kansas City, Missouri for his assistance in providing the supplemental clinical information. We also thank the hospital and research staff in participating centers for their dedication in working on this study. The opinions expressed in this article are those of the authors and do not represent the official position of the National Institutes of Health the Food and Drug Administration or the US Government. This work is supported in part by the intramural programs of the National Cancer Institute, Center for Cancer Research.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Pavletic, S., Zhou, G., Sobocinski, K. et al. Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia 21, 2452–2455 (2007). https://doi.org/10.1038/sj.leu.2404928
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404928
Keywords
This article is cited by
-
Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
Current Hematologic Malignancy Reports (2013)
-
Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML
Bone Marrow Transplantation (2008)